Daily Endocrinology Research Analysis
Three high-impact studies advance endocrine and metabolic research: a comprehensive mouse atlas of AAV vector tropism reveals unexpected targeting of endocrine tissues and a unique pan-endothelial/beta-cell profile for AAV4; a mechanistic study identifies epiregulin–EGFR–mTORC1 signaling as a regulator of osteoblast/osteoclast balance and reverses ovariectomy-induced bone loss; and a 16-center cohort validates a pragmatic two-step non-invasive pathway (FIB-4→LSM) to prognosticate liver-related e
Summary
Three high-impact studies advance endocrine and metabolic research: a comprehensive mouse atlas of AAV vector tropism reveals unexpected targeting of endocrine tissues and a unique pan-endothelial/beta-cell profile for AAV4; a mechanistic study identifies epiregulin–EGFR–mTORC1 signaling as a regulator of osteoblast/osteoclast balance and reverses ovariectomy-induced bone loss; and a 16-center cohort validates a pragmatic two-step non-invasive pathway (FIB-4→LSM) to prognosticate liver-related events in MASLD.
Research Themes
- Gene therapy vector tropism mapping for endocrine/metabolic targets
- EGFR–mTORC1 signaling in bone remodeling and osteoporosis therapeutics
- Non-invasive risk stratification pathway for MASLD prognosis
Selected Articles
1. A comprehensive atlas of AAV tropism in the mouse.
Systemic delivery of 10 AAV serotypes in mice revealed broad organ and cell tropism, including unexpected transduction of adrenals, testes, and ovaries. AAV4 exhibited pan-endothelial tropism and targeted pancreatic beta cells, and Cre-driven tdTomato activation provided superior sensitivity, creating a public atlas to guide serotype selection.
Impact: This resource enables rational vector selection for preclinical gene therapy, including endocrine targets such as pancreatic beta cells and adrenals. It uncovers novel AAV4 behavior (pan-endothelial and beta-cell tropism) with translational implications.
Clinical Implications: For endocrine gene therapy, these data support choosing specific serotypes (e.g., AAV4 for endothelial/beta-cell targeting) and anticipating off-target transduction (adrenals, gonads). It informs dosing, biodistribution, and safety planning in preclinical models.
Key Findings
- Cre-driven tdTomato fluorescence provided superior sensitivity for detecting transduced cells compared with ZsGreen.
- All serotypes except AAV3B and AAV4 showed high liver tropism after systemic delivery.
- Unexpected endocrine and reproductive tissues (adrenals, testes, ovaries) displayed transduction.
- Biodistribution of AAV genomes correlated with fluorescence readouts except in immune tissues.
- AAV4 demonstrated pan-endothelial tropism and targeted pancreatic beta cells.
Methodological Strengths
- Systematic, side-by-side assessment of 10 serotypes in both sexes with whole-body analysis.
- Use of Cre-Lox reporter (tdTomato) increased sensitivity for rare cell transduction.
Limitations
- Mouse-only preclinical data; human translational tropism may differ.
- Quantitative dosing-to-transduction relationships and immune tissue discrepancies require further study.
Future Directions: Validate tropism in disease models and large animals; engineer capsids leveraging AAV4 endothelial/beta-cell properties; integrate single-cell and spatial omics to refine cell-type targeting maps.
Gene therapy with adeno-associated virus (AAV) vectors requires knowledge of their tropism within the body. Here we analyze the tropism of 10 naturally occurring AAV serotypes (AAV3B, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAVrh8, AAVrh10, and AAVrh74) following systemic delivery into male and female mice. A transgene-expressing ZsGreen and Cre recombinase was used to identify transduction in a cell-dependent manner based on fluorescence. Cre-driven activation of tdTomato fluorescence offered superior sensitivity for transduced cells. All serotypes except AAV3B and AAV4 had high liver tropism. Fluorescence activation revealed transduction of unexpected tissues, including adrenals, testes, and ovaries. Rare transduced cells within tissues were also readily visualized. Biodistribution of AAV genomes correlated with fluorescence, except in immune tissues. AAV4 was found to have a pan-endothelial tropism while also targeting pancreatic beta cells. This public resource enables selection of the best AAV serotypes for basic science and preclinical applications in mice.
2. Epiregulin ameliorates ovariectomy-induced bone loss through orchestrating the differentiation of osteoblasts and osteoclasts.
Epiregulin promotes osteoblastogenesis and suppresses adipogenesis via EGFR-dependent mTORC1 inactivation and reduces osteoclastogenesis by downregulating RANKL, reversing OVX-induced trabecular bone loss. This identifies epiregulin–EGFR–mTORC1 as a mechanistic axis governing bone remodeling with therapeutic potential.
Impact: First demonstration that epiregulin orchestrates both osteoblast and osteoclast lineages via EGFR–mTORC1/RANKL, yielding in vivo bone protection. This opens a new therapeutic avenue for osteoporosis beyond antiresorptives/anabolics.
Clinical Implications: Targeting the epiregulin–EGFR–mTORC1 axis may offer dual anabolic–antiresorptive activity. Translational development will require careful safety profiling due to EGFR signaling in other tissues and malignancies.
Key Findings
- Epiregulin expression rises during osteogenesis and falls during adipogenesis in BMSCs.
- Epiregulin enhances osteoblast differentiation and inhibits adipocyte differentiation via EGFR.
- EGFR silencing abrogates epiregulin’s effects, indicating EGFR indispensability.
- Mechanistically, epiregulin–EGFR inactivates mTORC1; epiregulin downregulates RANKL and suppresses osteoclast differentiation.
- Recombinant epiregulin treatment in OVX mice increases bone formation, reduces resorption, and ameliorates cancellous bone loss.
Methodological Strengths
- Integrated in vitro lineage differentiation assays with in vivo OVX mouse model.
- Mechanistic dissection linking EGFR dependency to mTORC1 inactivation and RANKL modulation.
Limitations
- Preclinical study without human data; long-term safety and dosing remain unknown.
- Potential off-target effects given EGFR roles in multiple tissues and cancer biology.
Future Directions: Evaluate EREG agonism/antagonism strategies in larger animal models; test combination with standard osteoporosis agents; delineate safety in EGFR-rich tissues and neoplastic contexts.
Epiregulin plays a role in a range of biological activities including malignancies. This study aims to investigate the potential contribution of epiregulin to bone cell differentiation and bone homeostasis. The data showed that epiregulin expression was upregulated during osteogenesis but downregulated during adipogenesis. Functionally, epiregulin promoted osteoblast differentiation while inhibiting adipocyte differentiation from mesenchymal progenitor cells. Epidermal growth factor receptor (EGFR), one of the two known receptors for epiregulin, exerted opposing effects compared to epiregulin. Intriguingly, silencing EGFR almost completely abolished the dysregulation of osteoblast and adipocyte differentiation induced by epiregulin, suggesting that EGFR is indispensable for mediating epiregulin function. Further mechanistic exploration indicated that epiregulin/EGFR signaled via the inactivation of mechanistic target of rapamycin complex 1 (mTORC1) pathway. Moreover, epiregulin downregulated RANKL expression in bone marrow stromal cells (BMSCs) and inhibited the differentiation of bone marrow osteoclast precursor cells into osteoclasts. Treatment of ovariectomized female mice with recombinant epiregulin increased osteoblasts and bone formation, decreased osteoclasts and bone resorption, and ameliorated cancellous bone loss. Consistently, epiregulin treatment improved the potential of BMSCs to differentiate into osteoblasts. Collectively, this study has identified a critical role of epiregulin in regulating osteoblast differentiation through EGFR-mediated inactivation of the mTORC1 pathway, as well as osteoclast differentiation via a mechanism associated with RANKL signaling. Additionally, it highlights the potential of epiregulin as a strategy for combating osteoporosis.
3. Prognostic performance of the two-step clinical care pathway in metabolic dysfunction-associated steatotic liver disease.
In 12,950 MASLD patients, a two-step pathway (FIB-4 then LSM) stratified risk with 5-year LRE incidences of 0.5% (low), 1.0% (intermediate), and 10.8% (high). Using LSM thresholds (<10 and >15 kPa) further reduced the intermediate zone without sacrificing prognostic performance, supporting pragmatic non-invasive pathways.
Impact: Validates a scalable, non-invasive pathway that can be implemented in primary care to triage MASLD patients and anticipate liver-related outcomes, potentially reducing unnecessary biopsies.
Clinical Implications: Adopt FIB-4 screening followed by LSM to classify MASLD risk and guide referral intensity; consider refined LSM cutoffs (<10 and >15 kPa) to reduce indeterminate cases while maintaining prognostic accuracy.
Key Findings
- Baseline FIB-4 categorized 66.3% low-risk, 9.8% high-risk, and 23.9% intermediate-risk among 12,950 MASLD patients.
- Applying LSM (<8 and >12 kPa) to intermediate FIB-4 reclassified the cohort to 81.5% low-, 4.6% intermediate-, and 13.9% high-risk.
- Five-year cumulative LRE incidence was 0.5% (low), 1.0% (intermediate), and 10.8% (high).
- Replacing LSM with Agile 3+/Agile 4/FAST did not improve prediction or reduce indeterminate cases.
- Alternative LSM thresholds (<10 and >15 kPa) reduced the intermediate zone while preserving prognostic performance.
Methodological Strengths
- Large, multicenter longitudinal cohort (n=12,950) with hard clinical endpoints (LREs).
- Direct comparison of multiple second-line tests and threshold optimization.
Limitations
- Observational design susceptible to selection and center biases.
- External validation of refined LSM thresholds and device/protocol variability is needed.
Future Directions: Prospective implementation studies in primary care; cost-effectiveness analyses; integration with machine-learning models to further minimize indeterminate classifications.
BACKGROUND & AIMS: Current guidelines recommend a two-step approach for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) involving Fibrosis-4 index (FIB-4) followed by liver stiffness measurement (LSM) by vibration-controlled transient elastography (VCTE) or similar second-line tests. This study aimed to examine the prognostic performance of this approach. METHODS: The VCTE-Prognosis study was a longitudinal study of patients with MASLD who had undergone VCTE examinations at 16 centres from the US, Europe and Asia with subsequent follow-up for clinical events. The primary endpoint was incident liver-related events (LREs), defined as hepatic decompensation and/or hepatocellular carcinoma. RESULTS: Of 12,950 patients (mean age 52 years, 41% female, 12.1% LSM >12 kPa), baseline FIB-4, at cut-offs of 1.3 (or 2.0 for age ≥65) and 2.67, classified 66.3% as low-risk and 9.8% as high-risk, leaving 23.9% in the intermediate-risk zone. After classifying intermediate FIB-4 patients as low-risk if LSM was <8.0 kPa and high-risk if LSM was >12.0 kPa, 81.5%, 4.6%, and 13.9% of the full cohort were classified as low-, intermediate-, and high-risk, respectively. At a median (IQR) follow-up of 47 (23-72) months, 248 (1.9%) patients developed LREs. The 5-year cumulative incidence of LREs was 0.5%, 1.0% and 10.8% in the low-, intermediate- and high-risk groups, respectively. Replacing LSM with Agile 3+, Agile 4, and FAST did not reduce the intermediate-risk zone or improve event prediction. Classifying intermediate FIB-4 patients by LSM <10 kPa (low-risk) and >15 kPa (high-risk) reduced the intermediate-risk zone while maintaining predictive performance. CONCLUSIONS: The non-invasive two-step approach of FIB-4 followed by LSM is effective in classifying patients at different risks of LREs. IMPACT AND IMPLICATIONS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is emerging as one of the leading causes of cirrhosis and hepatocellular carcinoma worldwide, but only a minority of patients will develop these complications. Therefore, it is necessary to use non-invasive tests instead of liver biopsy for risk stratification. Additionally, as most patients with MASLD are seen in primary care instead of specialist settings, cost and availability of the tests should be taken into consideration. In this multicentre study, the use of the Fibrosis-4 index followed by liver stiffness measurement by vibration-controlled transient elastography effectively identified patients who would later develop liver-related events. The results support current recommendations by various regional guidelines on a clinical care pathway based on non-invasive tests to diagnose advanced liver fibrosis.